Literature DB >> 807846

Immunological studies of the anticryptococcal factor of normal human serum.

F Reiss, G Szilagyi, E Mayer.   

Abstract

Preliminary studies have shown a very high inhibitory activity in the alpha2 and gamma zone of human serum towards the growth of Cryptococcus neoformans. These findings are now corroborated by single radial immunodiffusion tests, which showed the some loss of IgA and IgM globulins and of the other three globulin fractions (ceruloplasmin, alpha2 macroglobulin and alpha2 HS glycoprotein) which migrate in the alpha2 zone. The data was obtained by single radial immunodiffusion tests. The losses were not statistically significant however. No change in the immunoglobulin content of the sera kept for 6 days in contact with a heat-killed suspension of C. neoformans was noted. These findings suggest, that the inhibitory activity of the normal human serum on the in-vitro growth of C. neoformans is due to the above mentioned globulin fractions and not to a single specific factor.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 807846     DOI: 10.1007/BF00491504

Source DB:  PubMed          Journal:  Mycopathologia        ISSN: 0301-486X            Impact factor:   2.574


  9 in total

1.  CHARACTERIZATION OF THE GROWTH INHIBITION FACTOR FOR CRYPTOCOCCUS NEOFORMANS (GIFC) IN HUMAN SERUM.

Authors:  G L BAUM; D ARTIS
Journal:  Am J Med Sci       Date:  1963-07       Impact factor: 2.378

2.  Growth inhibition of Cryptococcus neoformans by cell free human serum.

Authors:  G L BAUM; D ARTIS
Journal:  Am J Med Sci       Date:  1961-05       Impact factor: 2.378

3.  Capsule synthesis by Cryptococcus neoformans.

Authors:  M L LITTMAN
Journal:  Trans N Y Acad Sci       Date:  1958-05

4.  Stability of human immunoglobulin levels.

Authors:  M Allansmith; B McClellan; M Butterworth
Journal:  Proc Soc Exp Biol Med       Date:  1967-06

5.  The development of immunoglobulin levels in man.

Authors:  M Allansmith; B H McClellan; M Butterworth; J R Maloney
Journal:  J Pediatr       Date:  1968-02       Impact factor: 4.406

6.  Quantitation of immunoglobulins in normal children.

Authors:  J A Uffelman; W E Engelhard; C R Jolliff
Journal:  Clin Chim Acta       Date:  1970-04       Impact factor: 3.786

7.  Serum immunoglobulins. I. Levels in normal children and in uncomplicated childhood allergy.

Authors:  R H Buckley; S C Dees; W M O'Fallon
Journal:  Pediatrics       Date:  1968-03       Impact factor: 7.124

8.  Serum levels of immune globulins in health and disease: a survey.

Authors:  E R Stiehm; H H Fudenberg
Journal:  Pediatrics       Date:  1966-05       Impact factor: 7.124

9.  The anticryptococcal factor of blood serum. A preliminary report.

Authors:  G Szilagyi; F Reiss; J C Smith
Journal:  J Invest Dermatol       Date:  1966-03       Impact factor: 8.551

  9 in total
  6 in total

1.  Olfactory mucosa response in guinea pigs following intranasal instillation with Cryptococcus neoformans. A histological and immunocytochemical study.

Authors:  C Lima; J P Vital
Journal:  Mycopathologia       Date:  1994-05       Impact factor: 2.574

2.  Characterization of an anticryptococcal protein isolated from human serum.

Authors:  S Sridhar; M Ahluwalia; E Brummer; D A Stevens
Journal:  Infect Immun       Date:  2000-06       Impact factor: 3.441

Review 3.  Cryptococcosis in the era of AIDS--100 years after the discovery of Cryptococcus neoformans.

Authors:  T G Mitchell; J R Perfect
Journal:  Clin Microbiol Rev       Date:  1995-10       Impact factor: 26.132

Review 4.  Immunity in cryptococcosis: an overview.

Authors:  R A Fromtling; H J Shadomy
Journal:  Mycopathologia       Date:  1982-03-19       Impact factor: 2.574

5.  Further studies on the intracellular behavior of Torulopsis glabrata.

Authors:  V Otto; D H Howard
Journal:  Infect Immun       Date:  1976-08       Impact factor: 3.441

Review 6.  Serum therapy for tuberculosis revisited: reappraisal of the role of antibody-mediated immunity against Mycobacterium tuberculosis.

Authors:  A Glatman-Freedman; A Casadevall
Journal:  Clin Microbiol Rev       Date:  1998-07       Impact factor: 26.132

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.